Kepler Capital Markets set a €80.00 ($93.02) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a report issued on Monday morning. The brokerage currently has a buy rating on the stock.

Other equities analysts have also issued reports about the company. Credit Suisse Group set a €75.00 ($87.21) price target on Fresenius Medical Care AG & Co. KGaA and gave the company a neutral rating in a research note on Friday, December 7th. JPMorgan Chase & Co. set a €85.90 ($99.88) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Wednesday, February 27th. Berenberg Bank set a €88.65 ($103.08) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Tuesday, March 5th. HSBC set a €90.00 ($104.65) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Tuesday, December 4th. Finally, Sanford C. Bernstein set a €98.00 ($113.95) price objective on Fresenius Medical Care AG & Co. KGaA and gave the company a buy rating in a report on Friday, December 7th. Nine equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock presently has an average rating of Buy and an average price target of €82.68 ($96.14).

Shares of FME opened at €69.44 ($80.74) on Monday. Fresenius Medical Care AG & Co. KGaA has a 52-week low of €55.44 ($64.47) and a 52-week high of €91.74 ($106.67). The company has a current ratio of 1.25, a quick ratio of 0.96 and a debt-to-equity ratio of 58.49. The company has a market capitalization of $21.31 billion and a price-to-earnings ratio of 10.77.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

Read More: Why is the price-sales ratio important?

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.